Loading...
Olema Pharmaceuticals, Inc.
OLMA•NASDAQ
Healthcare
Biotechnology
$5.33
$0.19(3.70%)
Olema Pharmaceuticals, Inc. (OLMA) Financial Performance & Income Statement Overview
Review Olema Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-35.53%
↓ 35.53%
Net Income Growth
-33.95%
↓ 33.95%
Operating Cash Flow Growth
-24.63%
↓ 24.63%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-42.31%
↓ 42.31%
ROIC
-37.23%
↓ 37.23%
Olema Pharmaceuticals, Inc. (OLMA) Income Statement & Financial Overview
Review Olema Pharmaceuticals, Inc.'s (OLMA) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $94000.00 | $88000.00 |
| Gross Profit | $0.00 | $0.00 | -$94000.00 | -$88000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $32.30M | $33.23M | $29.11M | $29.88M |
| SG&A Expenses | $4.47M | $4.39M | $4.42M | $4.46M |
| Operating Expenses | $36.77M | $37.62M | $33.53M | $34.34M |
| Total Costs & Expenses | $36.77M | $37.62M | $33.53M | $34.34M |
| Interest Income | $3.29M | $2.93M | $3.11M | $3.35M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $116000.00 | $95000.00 | $94000.00 | $88000.00 |
| EBITDA | -$36.65M | -$37.53M | -$33.44M | -$34.25M |
| EBITDA Ratio | ||||
| Operating Income | -$36.77M | -$37.62M | -$33.53M | -$34.34M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $3.20M | $3.07M | $3.15M | $3.37M |
| Income Before Tax | -$33.57M | -$34.55M | -$30.38M | -$30.97M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$3.35M |
| Net Income | -$33.57M | -$34.55M | -$30.38M | -$30.97M |
| Net Income Ratio | ||||
| EPS | -$0.57 | -$0.60 | -$0.54 | -$0.56 |
| Diluted EPS | -$0.57 | -$0.60 | -$0.54 | -$0.56 |
| Weighted Avg Shares Outstanding | $74.31M | $57.26M | $56.28M | $55.57M |
| Weighted Avg Shares Outstanding (Diluted) | $74.31M | $57.26M | $56.28M | $55.57M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan